• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2018 Fiscal Year Final Research Report

Identification of novel therapeutic targets to block crosstalk of Wnt/Shh/Hypoxia-pathway feedforward loops in glioblastoma stem cells

Research Project

  • PDF
Project/Area Number 16K08722
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeMulti-year Fund
Section一般
Research Field Experimental pathology
Research InstitutionKyoto Pharmaceutical University

Principal Investigator

Nakata Susumu  京都薬科大学, 薬学部, 准教授 (80590695)

Co-Investigator(Kenkyū-buntansha) 藤田 貢  近畿大学, 医学部, 准教授 (40609997)
Project Period (FY) 2016-04-01 – 2019-03-31
Keywords膠芽腫幹細胞 / Wnt経路 / 低酸素応答シグナル / Shh経路 / シグナル間クロストーク
Outline of Final Research Achievements

Stat5b has been identified as a candidate for a novel therapeutic target, which is regulated by both Wnt and hypoxia responsible signaling pathways as a hub-gene in glioblastoma stem cells derived from a transposon-induced mouse model. On the other hand, it has also been clarified that the activity of the Shh pathway, which is maintained by Gli2 expression, forms a feedforward loop that activates Wnt pathway, by the signal crosstalk, in the shTP53/NRasG12V/EGFRvIII-driven glioblastoma stem cells, thereby promotes expansion of the glioblastoma stem cell population. The upregulation of Gli2 is maintained by a novel factor that regulates homeostasis of redox metabolism. These findings would be usuful for a development of a novel strategy targeting Stat5b or Gli2 to improve treatment for patients with glioblastoma.

Free Research Field

腫瘍細胞生物学

Academic Significance and Societal Importance of the Research Achievements

成人に最も多い脳腫瘍である膠芽腫は極めて予後不良な疾患であり、このような難治性癌は現在も深刻な問題として取り残されている。特に膠芽腫癌幹細胞を制御する因子や経路等の相互関係性や、特に階層性については不明な点が多いのが現状である。本研究により、複数の幹細胞制御機構のシグナルが集中するハブ遺伝子としての性質を有する新規治療標的分子の候補として、Stat5bおよびGli2を見出した。これらの因子を阻害することができれば、Wnt経路、Shh経路、低酸素応答シグナル等を一度に阻害することが出来ることが期待でき、より効率的に膠芽腫幹細胞を阻害できる、これまでにない新しい治療戦略に繋がる可能性がある。

URL: 

Published: 2020-03-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi